HELSINN GROUP AND EISAI INC. ANNOUNCE START OF PHASE III CLINICAL PROGRAM OF ORAL FIXED-DOSE COMBINATION OF NETUPITANT/ PALONOSETRON (300 mg/0.50 mg) FOR PREVENTION OF CHEMOTHERAPYINDUCED NAUSEA AND VOMITING (CINV)
![Comunicato stampa Helsinn 1.pdf Comunicato stampa Helsinn 1.pdf](/files/archives/p_Comunicato stampa Helsinn 1.jpg)
HELSINN GROUP AND EISAI INC. ANNOUNCE START OF PHASE III CLINICAL PROGRAM OF ORAL FIXED-DOSE COMBINATION OF NETUPITANT/ PALONOSETRON (300 mg/0.50 mg) FOR PREVENTION OF CHEMOTHERAPYINDUCED NAUSEA AND VOMITING (CINV)
Linkedin